MANHATTAN, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co., a Manhattan-headquartered investment bank and broker-dealer, today announced that it acted as the exclusive placement agent in connection with iSpecimen Inc.’s (Nasdaq: ISPC) private placement, raising approximately $5.5 million in gross proceeds before fees and expenses. The transaction reflects continued capital markets interest in differentiated healthcare technology platforms that support medical research and discovery. iSpecimen oper ...

Core Viewpoint - iSpecimen Inc. has entered into a securities purchase agreement with accredited investors, aiming to raise approximately $5.5 million through the issuance of Series C Convertible Preferred Stock [1][2][3] Group 1: Offering Details - The company will issue 6,875 shares of Series C Convertible Preferred Stock at a price of $800 per share, convertible into common stock at a conversion price of 85% of the closing price prior to each conversion date [2][3] - The offering is expected to close on or about December 31, 2025, pending customary closing conditions [3] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for marketing, working capital, and general corporate purposes [3] Group 3: Regulatory Information - The securities are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and have not been registered under the Act or applicable state laws, limiting their sale to accredited investors [4]

As filed with the Securities and Exchange Commission on December 19, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iSpecimen Inc. (Exact name of registrant as specified in its charter) Delaware 8731 27-0480143 (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No.) 8 Cabot Road, Suite 1800 Woburn, MA 081 ...

Financial Performance - Revenue decreased by approximately $2,555,000, or 96%, from approximately $2,662,000 for the three months ended September 30, 2024, to approximately $107,000 for the three months ended September 30, 2025[208]. - Specimen count decreased by 8,181, or approximately 97%, from 8,461 specimens in the three months ended September 30, 2024, to 280 specimens in the three months ended September 30, 2025[208]. - Revenue decreased by approximately $5,938,000, or 76%, from approximately $7,816,000 for the nine months ended September 30, 2024 to approximately $1,877,000 for the nine months ended September 30, 2025, primarily due to a decrease of 14,498 specimens, or approximately 74%[219]. - Cost of revenue decreased by approximately $2,673,000, or 67%, from approximately $3,979,000 for the nine months ended September 30, 2024 to approximately $1,306,000 for the nine months ended September 30, 2025, attributed to a 74% decrease in the number of specimens delivered[221]. - Net loss increased by approximately $1,340,795, or 93%, from $1,439,853 for the three months ended September 30, 2024, to $2,780,648 for the three months ended September 30, 2025[207]. Operating Expenses - Total operating expenses decreased by approximately $1,430,526, or 33%, from $4,367,340 for the three months ended September 30, 2024, to $2,936,814 for the three months ended September 30, 2025[207]. - Total operating expenses decreased by approximately $6,535,923, or 44%, from approximately $14,703,197 for the nine months ended September 30, 2024 to approximately $8,167,274 for the nine months ended September 30, 2025[218]. - General and administrative expenses decreased by approximately $1,481,000, or 37%, from approximately $4,052,000 for the nine months ended September 30, 2024 to approximately $2,571,000 for the nine months ended September 30, 2025[227]. - Fulfillment costs decreased by approximately $597,000, or 46%, from approximately $1,293,000 for the nine months ended September 30, 2024 to approximately $696,000 for the nine months ended September 30, 2025[226]. - Technology expenses decreased by approximately $946,000, or 37%, from approximately $2,579,000 for the nine months ended September 30, 2024 to approximately $1,633,000 for the nine months ended September 30, 2025[222]. Cash Flow and Financing - Cash and cash equivalents increased by approximately $904,350, or 48%, from approximately $1,878,408 as of December 31, 2024 to approximately $2,782,758 as of September 30, 2025[229]. - Net cash flows used in operating activities decreased by approximately $1,367,347, or 29%, from approximately $4,691,032 for the nine months ended September 30, 2024 to approximately $3,323,685 for the nine months ended September 30, 2025[229]. - Net cash provided by financing activities was approximately $5,228,000 for the nine months ended September 30, 2025, including $1,750,000 from PIPE financing and $4,000,000 from Underwritten financing[239]. Market and Operational Challenges - iSpecimen Inc. faced operational challenges due to the Russian-Ukrainian war, impacting approximately $1 million in purchase orders and leading to delays and margin reductions[185]. - Inflation has negatively impacted employee salaries and supply costs, although the costs of specimens have not been significantly affected due to long-term vendor contracts[242][243]. - The company has not experienced material supply chain issues affecting transportation, allowing timely deliveries during the nine months ended September 30, 2025[241]. Strategic Initiatives - iSpecimen Marketplace automates the procurement process, allowing researchers to efficiently find and manage specimens, enhancing operational efficiency for both researchers and biospecimen providers[159][161]. - The company is focused on enhancing pricing strategies and operational efficiencies to address current market conditions and improve liquidity[183][184]. - The company intends to rely on exemptions provided by the JOBS Act, remaining an "emerging growth company" until certain revenue or debt thresholds are met[248]. Stock and Securities - A reverse stock split of 1-for-20 was approved and became effective on September 13, 2024, allowing the company to regain compliance with Nasdaq listing requirements[171][172]. - The company raised gross proceeds of $4,998,464 from a public offering on October 31, 2024, with net proceeds of approximately $4,632,275 after offering costs[176][177]. - The company generated gross proceeds of $1,749,998 from a private placement on July 31, 2025, with net proceeds of approximately $1,649,998 after offering costs[166][167]. - The company issued 199,004 shares under an ATM agreement for gross proceeds of approximately $1,494,000 during the year ended December 31, 2024, resulting in net proceeds of approximately $1,239,000 after costs[168]. - iSpecimen Inc. entered into a Note Purchase Agreement for a loan of $1,000,000 with an interest rate of 18% per annum, which was fully paid off by October 31, 2024[174][175].

As filed with the Securities and Exchange Commission on October 6, 2025 Registration No. 333-289725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iSpecimen Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8731 27-0480143 (IRS Employer Identification No.) 8 Cabot Road, ...

As filed with the Securities and Exchange Commission on September 8, 2025 Registration No. 333-289725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iSpecimen, Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8731 27-0480143 (IRS Employer Identification No.) 8 Cabot Ro ...

Core Viewpoint - iSpecimen Inc. is pursuing a strategic initiative to integrate digital assets into its business model, aiming to establish a corporate treasury reserve of up to $200 million based on the Solana blockchain ecosystem [1][2]. Group 1: Strategic Initiative - The company has been approached by several cryptocurrency-related companies since announcing its intentions, presenting opportunities in tokenized real-world assets and highly ranked cryptocurrencies [2]. - iSpecimen is refining its approach to build a digital asset treasury, recognizing various opportunities while considering the acquisition of Locked Solana [3]. Group 2: Treasury Program Details - The planned treasury program includes purchasing SOL (the native token of the Solana network), including Locked SOL, through over-the-counter transactions with reputable cryptocurrency institutions [5]. - The company intends to fund the treasury program primarily from capital that may be raised over time [4]. Group 3: Investment Strategy - The company plans to deliver shareholder value through a buy and HODL strategy, purchasing locked SOL at a discount and staking Solana to increase yields for shareholders in the long term [6]. - A small percentage of the Solana holding will be allocated for spot trading to allow for diversification [6].

UNDER THE SECURITIES ACT OF 1933 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. 333-289725 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT iSpecimen, Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8731 27-0480143 (IRS Employer Identification No.) 8 Cabot Road ...

Core Insights - iSpecimen Inc. has successfully completed Milestone 1 in its digital transformation journey with Salestack Solutions, marking a significant step towards operational efficiency and scalability [1][3]. Group 1: Digital Transformation and Infrastructure - The completion of Milestone 1 involved enhancing the legacy iSpecimen Marketplace® infrastructure with Salestack's cloud-native architecture, which is expected to deliver immediate value [2]. - The modernized digital backbone of the iSpecimen Marketplace® is designed to ensure reliability, scalability, and faster time-to-market [2][4]. Group 2: Future Plans and Benefits - The successful completion of Milestone 1 positions iSpecimen to advance to Milestone 2, which will focus on integrating all parts of the business to create end-to-end efficiency across operations, customer engagement, and data management [3]. - The company anticipates unlocking greater efficiencies and enhancing marketplace capabilities as it progresses through the next milestones, aiming to create significant long-term value for shareholders, partners, and customers [4]. Group 3: Technical Enhancements - The new infrastructure includes features such as Infrastructure-as-Code (IaC) for automation and security, unified storage and workflows to reduce silos, and a future-ready foundation for seamless integration with major cloud providers [7]. - Key improvements from the new architecture include enhanced reliability through a resilient multi-cloud setup, improved security with automated safeguards, and accelerated innovation with faster development cycles [8].

As filed with the Securities and Exchange Commission on August 20, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Primary Standard Industrial Classification Code Number) Delaware 8731 27-0480143 (IRS Employer Identification No.) FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 iSpecimen, Inc. (Exact name of registrant as specified in its charter) (State or jurisdiction of incorporation or organization) 8 Cabot Road, Suite 1800 Woburn, MA 0 ...